de la Paz LJA

Idioma: Español
Referencias bibliográficas: 14
Paginas: 5-6
Archivo PDF: 68.10 Kb.

FRAGMENTO

La Asociación Norteamericana de Diabetes (ADA),¹ define la diabetes como un grupo de enfermedades metabólicas que se caracterizan por hiperglucemia, debida a defectos en la secreción de insulina, su acción, o ambas a la vez. En la mayoría de los casos, la diabetes tipo 2 se atribuye a una combinación de resistencia a la insulina y fracaso de las células beta, pero no está claro en que medida cada uno de estos factores contribuye al desarrollo de la enfermedad.²

REFERENCIAS (EN ESTE ARTÍCULO)

1. American Diabetes Association. Clinical practice recommendations 2000. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000; 23(1): S4-S19.

2. Ferrannini E. Insulin resistance versus insulin deficiency in noninsulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998; 19: 477-490.

3. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.

4. Fujimoto WY. Background and recruitment data for the US Diabetes Prevention Program. Diabetes Care 2000; 23(2):B11-B13.

5. Kruszynska YT, Olefsky JM. Cellular and molecular mechanisms of non-insulin-dependent diabetes mellitus. J Investing Med 1996; 44: 412-428.

6. American Diabetes Association. Diabetes facts and figures. http://www.diabetes.org/ada/facts.asp. Accessed November 21, 2000.

7. Harris MI, Klein R, Welbom TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15: 815-819.

8. Hamman RF, Mayer EJ, Moo-Young GA, Hildebrandt W, Marshall JA, Baxter J. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM. San Luis Valley Diabetes Study. Diabetes 1989; 38: 1231-1237.

9. Haffner SM, Mitchell BD, Pugh JA et al. Proteinuria in Mexican Americans and non-Hispanic whites with NIDDM. Diabetes Care 1989; 12: 530-536.

10. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. Diabetes in America. 2nd ed. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health 1995: 233-258.

11. United Kingdom prospective diabetes study group. UK Prospective diabetes study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 199O; 13: 1-11.

12. Polonsky KS, Sturis J, Bell GI. Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus— a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783.

13. United Kingdom prospective diabetes study group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet 1998; 352: 837-853.

14. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.